Market
Story
Eli Lilly's Zepbound Achieves 47% Greater Weight Loss Than Novo Nordisk's Wegovy in Phase 3B Trial
Dec 4, 2024, 11:52 AM
Eli Lilly & Co. has reported that its weight-loss drug Zepbound, also known as tirzepatide, outperformed Novo Nordisk A/S's Wegovy, or semaglutide, in a Phase 3B head-to-head clinical trial. The trial showed that Zepbound led to an average weight loss of 20.2% over 72 weeks, compared to 13.7% for Wegovy. Participants using Zepbound lost 50.3 lbs (22.8 kg), while those on Wegovy lost 33.1 lbs (15.0 kg). This 47% greater relative weight reduction has been highlighted by Eli Lilly as a significant achievement in the treatment of obesity. The results have led to a rise in Eli Lilly's stock price, reflecting investor confidence in the drug's potential.
View original story
Similar markets
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Increase investment in marketing existing drugs • 25%
Focus on improving CagriSema • 25%
Pursue mergers or acquisitions • 25%
Develop a new obesity drug • 25%
Trial cancelled • 25%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
No • 50%
Yes • 50%
Product recall • 25%
Other regulatory actions • 25%
Safety label update • 25%
No action taken • 25%
No • 50%
Yes • 50%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
Kidney disease • 25%
Heart disease • 25%
Stroke • 25%
Brain disorders • 25%
